Raxtozinameran

Comirnaty Omicron XBB.1.5

3 MCG / 0.2 ML SuspensionCanadaCancelledAuthorised 24 Oct 2023

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Comirnaty Omicron XBB.1.5 (10 Microgramos)/Dosis Dispersion InyectableSpain · 0,033 mg/ml · dispersión inyectable · Biontech Manufacturing GmbhSame brand
Comirnaty Omicron XBB.1.5 (3 Microgramos/Dosis) Concentrado Para Dispersion InyectableSpain · 0,015 mg/ml · concentrado para dispersion inyectable · Biontech Manufacturing GmbhSame brand
Comirnaty Omicron XBB.1.5 (30 Microgramos)/Dosis Dispersion InyectableSpain · 0,1 mg/ml · dispersión inyectable · Biontech Manufacturing GmbhSame brand
Comirnaty Omicron XBB.1.5Italy · Dispersione per preparazione iniettabile · Biontech Manufacturing GMBHSame brand

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Raxtozinameran

Comirnaty Omicron XBB.1.5

3 MCG / 0.2 ML SuspensionCanadaCancelledAuthorised 24 Oct 2023

Open in the registerAsk Osler about it

This page is kept for reference and is not offered to search engines.

In other countries

The same active substances on other registers, the same brand first.

Documents

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

The official texts, at the regulator.

Register entryHealth Canada

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Health Canada, Canada

Health Canada, Drug Product Database, drugproduct API, entire response observed 2026-10-10T15:12:07.336870+00:00; native facts projected by Prognia.

Licence: Open Government Licence Canada · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Raxtozinameran
Strength: 3 MCG / 0.2 ML
Dosage form: Suspension
Route: Intramuscular
Register: Canada (Health Canada)
Status: Cancelled
Status in the register: Cancelled Post Market
Authorised: 24 Oct 2023
Registration: DIN 02541866
Marketing authorisation holder: Biontech Manufacturing GMBH
ATC code: J07BN01
Group: Anti-infectives for systemic use
Supply: PRESCRIPTION, SCHEDULE D